A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 27 Sep 2017
At a glance
- Drugs Guadecitabine (Primary) ; Azacitidine; Cytarabine; Decitabine
- Indications Acute myeloid leukaemia
- Focus Registrational; Therapeutic Use
- Acronyms ASTRAL-1
- Sponsors Astex Pharmaceuticals; Otsuka Pharmaceutical
- 04 Jan 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Sep 2016 Status changed from active, no longer recruiting to recruiting.
- 16 Sep 2016 Status changed from recruiting to active, no longer recruiting.